Edition:
United Kingdom

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

89.82USD
23 Jul 2019
Change (% chg)

-- (--)
Prev Close
$89.82
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,780,851
52-wk High
$98.97
52-wk Low
$58.61

Select another date:

Mon, Jun 24 2019

Photo

Bristol-Myers plans to divest Celgene's psoriasis drug

Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.

Bristol-Myers plans to divest Celgene's psoriasis drug, shares slide

Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by U.S. antitrust regulators, and pushed back the closing of their $74 billion (58 billion pounds) deal.

UPDATE 3-Bristol-Myers plans to divest Celgene's psoriasis drug, shares slide

June 24 Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by U.S. antitrust regulators, and pushed back the closing of their $74 billion deal.

Bristol to divest Celgene's psoriasis treatment in FTC clearance push

June 24 Bristol-Myers Squibb Co said on Monday it would divest Celgene Corp's psoriasis treatment Otezla as the companies look to gain approval for their $74 billion deal from the U.S. Federal Trade Commission (FTC).

Bristol-Myers says shareholders vote to approve Celgene takeover

NEW YORK Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion acquisition of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Bristol-Myers says shareholders vote to approve Celgene takeover

NEW YORK Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion (56.6 billion pounds) acquisition of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

UPDATE 2-Bristol-Myers says shareholders vote to approve Celgene takeover

NEW YORK, April 12 Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion acquisition of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Bristol-Myers says shareholders vote to approve Celgene takeover

NEW YORK, April 12 Bristol-Myers Squibb Inc's shareholders voted to approve the drugmaker's $74 billion takeover of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Starboard abandons campaign to scuttle Bristol-Myers-Celgene deal

NEW YORK Activist hedge fund Starboard Value LP on Friday abandoned a campaign to convince Bristol-Myers Squibb Co shareholders to vote down the drugmaker's proposed $74 billion takeover of biotech Celgene Corp after the two leading proxy advisory firms backed the deal.

Starboard abandons campaign to scuttle Bristol-Myers-Celgene deal

NEW YORK Activist hedge fund Starboard Value LP on Friday abandoned a campaign to convince Bristol-Myers Squibb Co shareholders to vote down the drugmaker's proposed $74 billion takeover of biotech Celgene Corp after the two leading proxy advisory firms backed the deal.

Select another date: